Search - tctmd.com

Displaying 501 - 520 of 671

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong

January 31, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

Presentation

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Presenter: Andrew L. Frelinger

January 15, 2013

Presentation

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Presenter: J.P. Loh

January 09, 2013

Presentation

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Presenter: A. Wittfeldt

January 08, 2013

Presentation

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Presenter: P. Kohli

January 06, 2013

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

Presentation

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Presenter: A. Bellemain-Appaix

December 17, 2012

Presentation

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Presenter: Rossella Marcucci

December 12, 2012

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation

Bivalirudin for Primary PCI

Presenter: B. Hibbert

November 26, 2012

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

Presentation

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presenter: C. Quintavalle

November 15, 2012

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Advertisement

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Bivalirudin for Primary PCI

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Part 2: Antiplatelet Agents

Part 1: Oral Anticoagulants

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content